Next Article in Journal
Preparation and Characterization of Aptamers Against O,p’-DDT
Next Article in Special Issue
The Respiratory Phenotype of Pompe Disease Mouse Models
Previous Article in Journal
Analysis of Selenoprotein Expression in Response to Dietary Selenium Deficiency During Pregnancy Indicates Tissue Specific Differential Expression in Mothers and Sex Specific Changes in the Fetus and Offspring
Previous Article in Special Issue
Abnormal Lysosomal Positioning and Small Extracellular Vesicle Secretion in Arterial Stiffening and Calcification of Mice Lacking Mucolipin 1 Gene
Open AccessArticle

Rapamycin Re-Directs Lysosome Network, Stimulates ER-Remodeling, Involving Membrane CD317 and Affecting Exocytosis, in Campylobacter Jejuni-Lysate-Infected U937 Cells

1
Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy
2
Department of Pathogen Molecular Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK
3
Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, PA 19122, USA
4
Department of Medical Botechnologies, University of Siena, 53100 Siena, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(6), 2207; https://doi.org/10.3390/ijms21062207
Received: 30 January 2020 / Revised: 9 March 2020 / Accepted: 18 March 2020 / Published: 23 March 2020
The Gram-negative Campylobacter jejuni is a major cause of foodborne gastroenteritis in humans worldwide. The cytotoxic effects of Campylobacter have been mainly ascribed to the actions of the cytolethal distending toxin (CDT): it is mandatory to put in evidence risk factors for sequela development, such as reactive arthritis (ReA) and Guillain–Barré syndrome (GBS). Several researches are directed to managing symptom severity and the possible onset of sequelae. We found for the first time that rapamycin (RM) is able to largely inhibit the action of C. jejuni lysate CDT in U937 cells, and to partially avoid the activation of specific sub-lethal effects. In fact, we observed that the ability of this drug to redirect lysosomal compartment, stimulate ER-remodeling (highlighted by ER–lysosome and ER–mitochondria contacts), protect mitochondria network, and downregulate CD317/tetherin, is an important component of membrane microdomains. In particular, lysosomes are involved in the process of the reduction of intoxication, until the final step of lysosome exocytosis. Our results indicate that rapamycin confers protection against C. jejuni bacterial lysate insults to myeloid cells. View Full-Text
Keywords: Campylobacter jejuni; rapamycin; ER-remodeling; lysosome positioning and exocytosis; CD317/tetherin Campylobacter jejuni; rapamycin; ER-remodeling; lysosome positioning and exocytosis; CD317/tetherin
Show Figures

Graphical abstract

MDPI and ACS Style

Canonico, B.; Cesarini, E.; Montanari, M.; Di Sario, G.; Campana, R.; Galluzzi, L.; Sola, F.; Gundogdu, O.; Luchetti, F.; Diotallevi, A.; Baffone, W.; Giordano, A.; Papa, S. Rapamycin Re-Directs Lysosome Network, Stimulates ER-Remodeling, Involving Membrane CD317 and Affecting Exocytosis, in Campylobacter Jejuni-Lysate-Infected U937 Cells. Int. J. Mol. Sci. 2020, 21, 2207.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop